

Kihyun Kim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5209535/kihyun-kim-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232 papers	4,339 citations	33 h-index	60 g-index
239 ext. papers	5,248 ext. citations	3.8 avg, IF	4.6 L-index

#	Paper	IF	Citations
232	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.. <i>Annals of Hematology</i> , 2022 , 101, 1217	3	
231	Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.. <i>Annals of Laboratory Medicine</i> , 2022 , 42, 558-565	3.1	1
230	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).. <i>International Journal of Hematology</i> , 2022 , 1	2.3	
229	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. <i>British Journal of Haematology</i> , 2021 , 193, 101-112	4.5	3
228	Exploration of the Appropriate NT-Probnp Level for AL Amyloidosis Staging. <i>Blood</i> , 2021 , 138, 3777-3777	2.2	
227	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021 , 11, 190	7	2
226	Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders. <i>Korean Journal of Medicine</i> , 2021 , 96, 371-381	0.5	
225	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. <i>British Journal of Haematology</i> , 2021 ,	4.5	
224	tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method. <i>Analytical Chemistry</i> , 2021 , 93, 14088-14098	4.09	0
223	Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Infections in Tertiary Care Setting?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
222	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021 , 194, 784-788	4.5	2
221	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 668-678	2.5	1
220	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2021 ,	10.7	8
219	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 2361-2371	40	46
218	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 737-749	3.2	1
217	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , 2021 , 35, 1797-1802	10.7	5
216	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021 , 113, 81-91	2.3	1

215	Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis. <i>Journal of Cancer</i> , 2021 , 12, 2825-2834	4.5	5
214	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , 2021 , 29, 4969-4977	3.9	0
213	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. <i>Annals of Hematology</i> , 2021 , 100, 1065-1077	3	2
212	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021 , 385, 46-58	59.2	61
211	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021 , 46, 100786	2.3	
210	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. <i>Current Problems in Cancer</i> , 2021 , 46, 100788	2.3	
209	Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. <i>International Journal of Hematology</i> , 2021 , 114, 653-663	2.3	0
208	Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
207	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020 , 10, 111	7	3
206	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020 , 112, 84-95	2.3	0
205	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020 , 17, e1003091	11.6	5
204	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020 , 103, 1630-1636	3.1	3
203	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2714-2721	1.9	3
202	99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: Potential clinical implications. <i>Medicine (United States)</i> , 2020 , 99, e18905	1.8	3
201	Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study. <i>Blood</i> , 2020 , 136, 14-14	2.2	
200	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020 , 136, 30-31	2.2	
199	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. <i>Blood</i> , 2020 , 136, 11-11	2.2	1
198	Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. <i>Clinical Cancer Research</i> , 2020 , 26, 935-944	12.9	23

197	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020 , 136, 48-50	2.2	7
196	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , 2020 , 136, 7-8	2.2	12
195	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 53-54	2.2	6
194	Ixazomib-dexamethasone (Ixa-Dex) vs physician's choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8546-8546	2.2	5
193	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. <i>International Journal of Heart Failure</i> , 2020 , 2, 231	1.3	5
192	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020 , 34, 1875-1884	10.7	77
191	Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e97-e104	2	1
190	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). <i>American Journal of Hematology</i> , 2020 , 95, 413-421	7.1	6
189	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020 , 99, 309-319	3	4
188	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020 , 20, 803	4.8	7
187	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , 2020 , 40, 88-91	3.1	0
186	Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis. <i>Scientific Reports</i> , 2019 , 9, 7746	4.9	10
185	Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients. <i>European Journal of Cancer Care</i> , 2019 , 28, e13089	2.4	5
184	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM163 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1312-1313	4.7	6
183	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019 , 98, 941-949	3	7
182	Prognostic values of novel biomarkers in patients with AL amyloidosis. <i>Scientific Reports</i> , 2019 , 9, 12200	4.9	2
181	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2019 , 34, 579-588	3.2	5
180	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2051-2059	4.4	1

179	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , 2019 , 9, 83	7	4
178	A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model. <i>Immunology Letters</i> , 2019 , 216, 21-27	4.1	
177	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019 , 134, 1866-1866	2.2	21
176	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). <i>Blood</i> , 2019 , 134, 139-139	2.2	29
175	Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center. <i>Blood</i> , 2019 , 134, 5585-5585	2.2	
174	First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism. <i>Annals of Laboratory Medicine</i> , 2019 , 39, 96-98	3.1	
173	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 92-95	2.8	8
172	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019 , 109, 79-90	2.3	7
171	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018 , 53, 967-976	4.4	9
170	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2305-2317	1.9	9
169	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 923-929	4.7	9
168	Development and Validation of Mass Spectrometry-Based Targeted Analysis for Amyloid Proteins. <i>Proteomics - Clinical Applications</i> , 2018 , 12, e1700106	3.1	3
167	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018 , 181, 707-710	4.5	7
166	Prognostic Value of Baseline F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study. <i>Korean Journal of Radiology</i> , 2018 , 19, 481-488	6.9	8
165	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	24
164	Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. <i>Genome Research</i> , 2018 , 28, 1217-1227	9.7	90
163	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018 , 132, 1996-1996	2.2	10
162	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. <i>Blood</i> , 2018 , 132, 3347-3347	2.2	

161	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018 , 140, 146-156	2.7	10
160	Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018 , 103, 2088-2096	6.6	133
159	Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience. <i>Annals of Laboratory Medicine</i> , 2018 , 38, 196-203	3.1	7
158	Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. <i>British Journal of Haematology</i> , 2017 , 176, 743-749	4.5	11
157	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017 , 6, 100-108	4.8	4
156	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017 , 92, 1280-1286	7.1	23
155	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017 , 36, 67-71	4.8	12
154	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017 , 47, 995-1001	2.8	3
153	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017 , 8, 37605-37618	3.3	4
152	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017 , 8, 79517-79526	3.3	13
151	Clinical manifestation and prognostic features of extramedullary plasmacytomas.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e19516-e19516	2.2	
150	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016 , 16, 613	4.8	14
149	Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer. <i>Journal of Infection</i> , 2016 , 72, 233-9	18.9	6
148	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016 , 95, 325-35	3	25
147	Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2016 , 128, 2130-2130	2.2	1
146	Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. <i>Oncotarget</i> , 2016 , 7, 68350-68359	3.3	4
145	Clinical utility of comprehensive approach to detect genetic abnormalities in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8034-8034	2.2	
144	A Prognostic Scoring System for Patients with Multiple Myeloma Who Were Classified Stage II By Revised International Staging System. <i>Blood</i> , 2016 , 128, 3284-3284	2.2	

143	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016 , 128, 4414-4414	2.2	
142	Patterns of Treatment Failure in Systemic Light Chain Amyloidosis with Long-Term Survival after Chemotherapy. <i>Blood</i> , 2016 , 128, 2132-2132	2.2	
141	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016 , 128, 4445-4445	2.2	
140	Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. <i>Blood</i> , 2016 , 128, 4650-4650 ^{2.2}	2.2	
139	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 5683-5683	2.2	
138	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016 , 51, 193-199	1.4	3
137	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. <i>Oncotarget</i> , 2016 , 7, 47127-47133	3.3	5
136	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2016 , 73, 496-505	18.9	28
135	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016 , 95, 911-9	3	2
134	The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 227-35	2	14
133	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015 , 76, 636-43	2.3	8
132	Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 103	22.4	33
131	Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma. <i>Journal of Clinical Laboratory Analysis</i> , 2015 , 29, 505-10	3	5
130	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 126, 746-56	2.2	12.2
129	Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report. <i>Case Reports in Nephrology and Dialysis</i> , 2015 , 5, 180-6	1.3	2
128	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015 , 35, 2363-9	7.9	19
127	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015 , 50, 7-18	1.4	3
126	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015 , 6, 42803-12	3.3	16

125	A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. <i>Blood</i> , 2015 , 126, 4239-4239	2.2	9
124	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. <i>Blood</i> , 2015 , 126, 4240-4240	2.2	3
123	Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 496-505	2.5	64
122	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 675-83	2.5	2
121	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2015 , 126, 1904-1904	2.2	
120	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2015 , 126, 5160-5160	2.2	
119	Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. <i>Anticancer Research</i> , 2015 , 35, 3081-9	2.3	18
118	Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. <i>Annals of Hematology</i> , 2014 , 93, 113-21	3	12
117	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , 2014 , 93, 1353-61	3	15
116	A case of Fanconi syndrome accompanied by crystal depositions in tubular cells in a patient with multiple myeloma. <i>Kidney Research and Clinical Practice</i> , 2014 , 33, 112-5	3.6	4
115	Cardiac amyloidosis without increased left ventricular wall thickness. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 781-9	6.4	24
114	Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014 , 2014, 253243	3	4
113	Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma. <i>BioMed Research International</i> , 2014 , 2014, 437852	3	18
112	Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. <i>American Journal of Hematology</i> , 2014 , 89, 751-6	7.1	60
111	Spinal cord compression in multiple myeloma: a single center experience. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2395-7	1.9	3
110	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014 , 21, 261-6	2.7	17
109	Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. <i>Acta Haematologica</i> , 2014 , 131, 193-9	2.7	18
108	Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. <i>Acta Haematologica</i> , 2014 , 132, 226-32	2.7	6

107	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20698-e20698	2.2	1
106	The Clinical Impact of Thalidomide Maintenance on Progression Free Survival and Postrelapse Survival after Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple myeloma. <i>Blood</i> , 2014 , 124, 3975-3975	2.2	
105	The Prognostic Impact of Inflammatory Factors for Survival in Patients with Newly Diagnosed Multiple Myeloma Who Were Treated with Thalidomide Containing Induction Chemotherapy Underwent Autologous Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 5896-5896	2.2	
104	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014 , 34, 4299-306	2.3	7
103	Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis. <i>American Journal of Hematology</i> , 2013 , 88, 52-5	7.1	9
102	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , 2013 , 37, 1070-6	2.7	12
101	Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013 , 20, 204-11	2.7	5
100	Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma. <i>Blood Research</i> , 2013 , 48, 233-4	1.4	3
99	Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. <i>Journal of Korean Medical Science</i> , 2013 , 28, 80-6	4.7	3
98	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. <i>Blood</i> , 2013 , 122, 3189-3189	2.2	4
97	Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. <i>Blood</i> , 2013 , 122, 5379-5379	2.2	
96	Post-Transplant Immune Monitoring In Patients Receiving Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013 , 122, 5486-5486	2.2	
95	Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. <i>American Journal of Hematology</i> , 2012 , 87, 37-41	7.1	20
94	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: A phase II study. <i>Journal of Clinical Hematology</i> , 2012 , 2012, 213-21	3	13
93	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012 , 30, 368-75	4.3	16
92	Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 118-26	2	2
91	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8097-8097	2.2	1
90	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KtMM-04 Study) Interim Analysis. <i>Blood</i> , 2012 , 120, 3106-3106	2.2	

89	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , 2011 , 90, 1391-8	3	37
88	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011 , 93, 383-388	2.3	15
87	Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 205-13	1.9	17
86	Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 353-7	2.8	24
85	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. <i>Blood</i> , 2011 , 118, 1990-1990	2.2	
84	Early Response to Bortezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. <i>Blood</i> , 2011 , 118, 5138-5138	2.2	
83	Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC,. <i>Blood</i> , 2011 , 118, 3563-3563	2.2	
82	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. <i>British Journal of Haematology</i> , 2010 , 149, 537-49	4.5	107
81	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. <i>Annals of Hematology</i> , 2010 , 89, 201-6	3	23
80	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). <i>Annals of Hematology</i> , 2010 , 89, 188-97	3	10
79	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. <i>Annals of Hematology</i> , 2010 , 89, 905-12	3	15
78	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. <i>Annals of Hematology</i> , 2010 , 89, 1011-8	3	9
77	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010 , 92, 52-7	2.3	34
76	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 197, 117-21		12
75	Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2010 , 116, 4371-4371	2.2	
74	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1110-8	1.9	7
73	Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6027-32	2.2	254
72	Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009 , 122, 200-10	2.7	27

71	Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2009 , 83, 108-118	3.8	15
70	Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , 2009 , 88, 111-9	3	27
69	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , 2009 , 88, 1099-106	3	17
68	Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 463-70	4.7	46
67	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 757-63	1.9	51
66	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. <i>Blood</i> , 2009 , 113, 4309-18	2.2	55
65	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009 , 114, 1792-1792	2.2	1
64	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. <i>Blood</i> , 2009 , 114, 4661-4661	2.2	
63	First Asia-Pacific Co-Operative Multicenter Multiple Myeloma Clinical Trial: Preliminary Results of the BtZ/D/DAZZLED Study.. <i>Blood</i> , 2009 , 114, 4940-4940	2.2	
62	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009 , 114, 4881-4881	2.2	
61	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. <i>Blood</i> , 2009 , 114, 4298-4298	2.2	
60	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 1110-1110	2.2	1
59	Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8, 237-40		52
58	Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1356-64	4.7	109
57	Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis?. <i>Acta Haematologica</i> , 2008 , 120, 199-206	2.7	26
56	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008 , 25, 447-50	3.7	5
55	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.. <i>Blood</i> , 2008 , 112, 3330-3330	2.2	1
54	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. <i>Blood</i> , 2008 , 112, 5184-5184	2.2	1

53	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. <i>Blood</i> , 2008 , 112, 4219-4219	2.2	
52	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. <i>Blood</i> , 2008 , 112, 4109-4109	2.2	
51	Velcade [®] , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. <i>Blood</i> , 2008 , 112, 2785-2785	2.2	
50	Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of Korean all-ages group and Western younger age group. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 580-6		12
49	Generation and Qualification of Functionally Active Leukemia-derived DCs from Malignant Blasts in Acute Leukemia. <i>The Korean Journal of Hematology</i> , 2007 , 42, 264		
48	Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. <i>American Journal of Hematology</i> , 2007 , 82, 446-52	7.1	39
47	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007 , 31, 359-64	2.7	31
46	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. <i>European Journal of Haematology</i> , 2007 , 79, 287-91	3.8	13
45	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. <i>Annals of Hematology</i> , 2007 , 86, 493-8	3	114
44	Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. <i>Clinical Cancer Research</i> , 2007 , 13, 3250-4	12.9	37
43	Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 716-22	1.9	25
42	Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007 , 258, 90-7	9.9	18
41	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 972-8	2.2	245
40	Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007 , 48, 937-43	1.9	4
39	Single and Tandem Autologous Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: A Korean Multicenter Retrospective Study.. <i>Blood</i> , 2007 , 110, 5132-5132	2.2	1
38	A Multicenter Comparison of Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation with Tandem Autologous Stem Cell Transplantation in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 940-940	2.2	1
37	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE [®] , Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial. <i>Blood</i> , 2007 , 110, 952-952	2.2	3
36	Velcade [®] , Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.. <i>Blood</i> , 2007 , 110, 4831-4831	2.2	

35	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. <i>Blood</i> , 2007 , 110, 1361-1361	2.2	
34	The Optimal Processing Time of Adipose-Derived Mesenchymal Stem Cell after Lipoaspiration.. <i>Blood</i> , 2007 , 110, 4107-4107	2.2	
33	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. <i>Blood</i> , 2007 , 110, 4843-4843	2.2	
32	Prediction of Survival in Patients with Myelodysplastic Syndrome According to WHO Classification-Based Prognostic Scoring System (WPSS).. <i>Blood</i> , 2007 , 110, 4617-4617	2.2	
31	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , 2006 , 85, 285-90	3	17
30	Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , 2006 , 85, 781-6	3	37
29	Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , 2006 , 77, 304-8	3.8	8
28	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1253-9	1.9	14
27	Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 612-8	2.2	457
26	New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 837-44	4.7	17
25	Interferon- β resistance can be reversed by inhibition of IFN- β induced COX-2 expression potentially via STAT1 activation in A549 cells. <i>Oncology Reports</i> , 2006 , 15, 1541	3.5	
24	Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006 , 30, 1253-8	2.7	9
23	A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. <i>International Journal of Hematology</i> , 2006 , 83, 309-13	2.3	30
22	Intestinal Marginal Zone B-Cell Lymphoma of MALT Type: Clinical Manifestation and Outcome of a Rare Disease.. <i>Blood</i> , 2006 , 108, 4742-4742	2.2	
21	Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. <i>Blood</i> , 2006 , 108, 4670-4670	2.2	
20	Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 334, 313-8	3.4	50
19	Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005 , 41, 1402-8	7.5	136
18	Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. <i>British Journal of Haematology</i> , 2005 , 131, 59-66	4.5	40

17	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. <i>Cellular Signalling</i> , 2005 , 17, 111-9	4.9	22
16	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. <i>Blood</i> , 2005 , 106, 5415-5415	2.2	
15	A Comparison of 3 Staging Systems for the Outcome Following Autologous Stem Cell Transplantation (ASCT) in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 5479-5479	2.2	
14	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 1491-1491	2.2	
13	Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. <i>Blood</i> , 2005 , 106, 3500-3500	2.2	
12	Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment. <i>Leukemia and Lymphoma</i> , 2004 , 45, 339-44	1.9	39
11	Primary pulmonary non-Hodgkin's lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 510-4	2.8	83
10	Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. <i>Oncology</i> , 2004 , 66, 32-7	3.6	19
9	L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. <i>Journal of Cellular Biochemistry</i> , 2004 , 93, 257-70	4.7	34
8	L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 2180-95	5.6	68
7	A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 3162-3162	2.2	1
6	CHOP Followed by Radiotherapy for Localized Aggressive Primary Gastric Lymphoma: Results of a Multi Center Phase II Study.. <i>Blood</i> , 2004 , 104, 3306-3306	2.2	
5	Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2002 , 71, 75-9	7.1	60
4	Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 354-7	2.7	14
3	Aggressive natural killer cell leukemia: clinical features and treatment outcome. <i>Haematologica</i> , 2002 , 87, 1343-5	6.6	47
2	Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. <i>Human Gene Therapy</i> , 2001 , 12, 671-84	4.8	108
1	Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1-7	2.7	